Advertisement
Canada markets close in 5 hours 7 minutes
  • S&P/TSX

    22,164.62
    -79.40 (-0.36%)
     
  • S&P 500

    5,545.18
    +8.16 (+0.15%)
     
  • DOW

    39,276.15
    -31.85 (-0.08%)
     
  • CAD/USD

    0.7334
    -0.0013 (-0.17%)
     
  • CRUDE OIL

    83.81
    -0.07 (-0.08%)
     
  • Bitcoin CAD

    76,053.16
    -2,211.27 (-2.83%)
     
  • CMC Crypto 200

    1,152.98
    -55.72 (-4.61%)
     
  • GOLD FUTURES

    2,390.80
    +21.40 (+0.90%)
     
  • RUSSELL 2000

    2,020.65
    -15.97 (-0.78%)
     
  • 10-Yr Bond

    4.3080
    -0.0470 (-1.08%)
     
  • NASDAQ

    18,280.38
    +92.08 (+0.51%)
     
  • VOLATILITY

    12.35
    +0.09 (+0.73%)
     
  • FTSE

    8,188.65
    -52.61 (-0.64%)
     
  • NIKKEI 225

    40,912.37
    -1.28 (-0.00%)
     
  • CAD/EUR

    0.6773
    -0.0019 (-0.28%)
     

Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024

NEW YORK (AP) — Stocks that traded heavily or had substantial price changes on Friday:

Nike Inc., down $18.82 to $75.37.

The global sportswear giant expects its revenue will slip during the current fiscal year.

Infinera Corp., up 83 cents to $6.09.

Nokia is buying the communications equipment maker for about $2.3 billion.

Kura Sushi USA Inc., down $19.30 to $63.09.

The sushi chain gave investors a disappointing fiscal third-quarter financial update.

Accolade Inc., down $2.81 to $3.58.

The healthcare technology company cut its revenue forecast for the fiscal year.

Protagonist Therapeutics Inc., up $2.77 to $34.65.

ADVERTISEMENT

The biopharmaceutical company will join the S&P Small-Cap 600 on July 3.

PTC Therapeutics Inc., down $4.08 to $30.58.

European regulators rejected the biopharmaceutical company's Duchenne muscular dystrophy treatment.

Freeport-McMoRan Inc., up 28 cents to $48.60.

The copper miner gained ground along with prices for the base metal.

Crown Crafts Inc., up 23 cents to $5.23.

The maker of infant and toddler bedding reported fiscal fourth-quarter earnings and revenue gains.